About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

RECRUITINGPhase 2NCT06880419

Anti-CD25 rhMAb for aGVHD Prevention in High-Risk Adults Using the daGOAT Model

To assess the efficacy and safety of using recombinant humanized anti-CD25 monoclonal antibody injection as a prophylactic strategy for reducing the incidence of severe acute graft-versus-host disease...

Lead sponsor: Institute of Hematology & Blood Diseases Hospital, China•1 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Contacts

erlie jiang

CONTACT

+86-15122538106 [email protected]

yigeng cao

CONTACT

+86-18622477066 [email protected]

Sponsors

Lead Sponsor

Institute of Hematology & Blood Diseases Hospital, China

Age

16 - No limit years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•1. Age ≥ 16 years, regardless of gender.
•2. Patients with hematologic disorders who are scheduled to receive allo-HSCT.
•3. Voluntarily join this study, sign the informed consent form, have good compliance, and be willing to cooperate with follow-up.

Exclusion Criteria

•1. Patients who have received a second or multiple transplants.
•2. Patients who are allergic to, or intolerant of, a recombinant humanized anti-CD25 monoclonal antibody injection.
•3. Pregnant or lactating female patients or female patients who are unable to take effective contraceptive measures during the entire trial period.

Related studies

RECRUITINGPhase 1

A Phase Ib Clinical Study of AC-003 Capsules in Subjects With aGVHD.

NCT07070674 · Acute Graft-versus-Host Disease

RECRUITINGPhase 3

Effect of Stem Cell Infusion Time on aGVHD in Patients With Nonmalignant Hematologic Diseases

NCT06294691 · Acute Graft-versus-host Disease

RECRUITINGPhase 2

MAGIC Ruxolitinib for aGVHD

NCT06936566 · Acute Graft-versus-host Disease, Allogeneic Bone Marrow Transplantation, and more

Active Not Recruiting

Dendritic Cells in Patients With Acute or Chronic Skin Graft Versus Host Disease

NCT02611180 · Acute Graft-versus-host Disease, Acute GVHD, and more

Active Not RecruitingPhase 2

Trial of Efficacy and Safety of MC0518 Versus Best Available Therapy in Participants With Steroid-Refractory Acute Graft Versus Host Disease

NCT06075706 · Steroid-refractory Acute Graft-versus-host Disease

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: August 8, 2025Terms

Trial snapshot

StatusRECRUITING

PhasePHASE2

Enrollment174

Start dateMar 2025

Last updatedAug 8, 2025

Condition

Acute Graft-versus-Host Disease

Locations shown

Institute of Hematology & Blood Diseases Hospital

Tianjin, Tianjin Municipality

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: August 8, 2025Data synced to Clareo: May 25, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions